Bronchogen

Bronchogen – Respiratory Bioregulator Peptide for Lung and Bronchial Research

Bronchogen is a DNA‑interacting tetrapeptide composed of alanine, glutamic acid, aspartic acid, and leucine (Ala‑Glu‑Asp‑Leu) that has been studied as a lung‑targeted bioregulator. Experimental work suggests Bronchogen can modulate gene expression programs involved in bronchial epithelial differentiation, inflammation resolution, and surfactant biology, making it a versatile tool for respiratory research models. (https://pubmed.ncbi.nlm.nih.gov/30199201/

https://exploring-peptides.com/peptide-wikipedia/bronchogen/)

Key features

• Bronchial epithelium support: Bronchogen has been reported to restore the structure and cellular composition of damaged bronchial epithelium in animal models, normalizing goblet‑cell, ciliated‑cell, and inflammatory‑cell profiles.

• DNA and gene‑expression modulation: In vitro and in vivo research indicates Bronchogen can bind specific DNA regions and influence expression of key lung‑identity genes such as NKX2‑1, SCGB1A1, SCGB3A2, FOXA1, and FOXA2, supporting epithelial maintenance and repair.

• Anti‑inflammatory and immunologic actions: Studies show reductions in neutrophil‑dominant inflammation, normalization of pro‑inflammatory cytokines like TNF‑α and IL‑8, and increases in secretory IgA in the airways, pointing to local immune‑defense support.

• Surfactant and mucin regulation: Bronchogen appears to influence surfactant protein production (e.g., SP‑B) and mucin gene expression, processes central to alveolar stability, mucus quality, and efficient gas exchange.

  
  

Research applications

Bronchogen is used in experimental models exploring:

• Chronic obstructive pulmonary disease (COPD), chronic bronchitis, and long‑term airway injury, where it is studied for effects on epithelial remodeling, emphysema‑like changes, and inflammatory profiles.

• Asthma and reactive airway disease, assessing airway inflammation, mucus production, and bronchoalveolar immune markers.

• Environmental and toxin‑induced lung damage (e.g., NO₂ exposure, smoke, pollutants), focusing on barrier integrity, tissue remodeling, and recovery of lung architecture.

• Fundamental respiratory bioregulation, including chromatin remodeling, DNA–peptide interactions, and aging‑related changes in bronchial epithelial function.

  
  

Recommended handling

• For controlled laboratory research use only, by qualified professionals.

• Typically supplied as a lyophilized powder (e.g., 10–20 mg) in sterile glass vials; store in a cool, dry environment away from light and moisture, and follow institutional SOPs for peptide storage, reconstitution, aliquoting, and disposal.

• Investigators should consult current literature when designing dosing, exposure schedules, and outcome measures such as histology, surfactant and mucin markers, cytokine panels, and lung‑function proxies.

  
  

Important disclaimer

All compounds sold by Rocky Peptide Chain, including Bronchogen, are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding relief of respiratory symptoms, improvement of lung function, disease modification, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.